

Strategic Research & Innovation Committee

minutes

Minutes of the Strategic Research & Innovation meeting held on 14th May 2024

Present:	Bob Burgoyne Prof Jay Wright Keith Wilson Jonathan Mathews James Thomson Thomas Pharaoh Prof Reecha Sofat	Non-Executive Director (Chair) Clinical Lead for Research and Director of Research & Innovation Patient Research Ambassador Chief Operating Officer & Deputy CEO Chief Finance Officer Director of Strategy Head of Department Pharmacology and Therapeutics, University of Liverpool
In Attendance:	Mark Bellis Jennifer Ohlsson	LJMU Senior Executive Assistant (Minutes)
Apologies for Absence:	Prof Raphaela Kane Liz Bishop Manoj Kuduvalli Claudette Elliot Jennifer Crooks	Pro Vice Chancellor, Faculty of Health, LJMU Chief Executive Officer Medical Director Non-Executive Director Deputy Director of Research & Innovation

1. Apologies for Absence

Apologies noted above.

2. Declarations of Interest

James Thomson and Thomas Pharaoh noted joint role with Clatterbridge Cancer Centre.

3. Minutes of the previous meeting on 27th February 2023

Minutes of the previous meeting on 27th February were agreed as an

accurate record of the meeting.

4. Action log

Action 1: Criteria to gain University Hospital status on agenda for discussion.

Action 2: Medical Director to be included in the membership on the Terms of Reference.

5. UHA Status Update

An update was provided on the criteria for gaining University Hospital status update and colleagues were asked to note the paper circulated prior to the meeting. It was noted that a gap analysis is currently being undertaken on the criteria. The Trust meet all areas except four areas of ambiguity: an MoU with Universities, a considerable number of honorary consultant contracts, £200k worth of research capacity funding and the need to demonstrate significant education support. There is hope that once these four areas are clarified, the Trust can write a request for consideration of University Hospital Status.

Comments and questions were welcomed, and it was noted that there is a similar programme of work happening at Clatterbridge Cancer Centre.

A further query was raised on whether having a shared CEO and CFO will have an impact. It was stated that it is not anticipated that it would have an impact, however, could be beneficial to demonstrate a collaborative approach.

6. Research Performance Reporting

An overview of the research performance report was given, which provided an overview of the research accomplishments for the financial year 2023/2024. It was noted that LHCH have had another very good year across their research activity.

Looking forward to 2024-25, the Research Department aim to; Increase commercial activity with a specific focus on CTIMPS, do more AHP/Nurse led research, increase breadth of research to include areas such as critical care and more surgical studies, Increase CRF activity with first CVD in HF finally open to recruit, recruit a Matron B8a post, undertake a comparative effectiveness study in ITU sponsored by LHCH, Drive forward the use of data to embed research across the organisation and to aid and support evidence-based decision making and improved set up time, especially the commercial studies

Comments and questions were welcomed, and it was noted that it is good to see the pivoting between commercial and non-commercial. It was confirmed that there is now a band 5 finance officer to focus on the billing and invoicing.

Performance reporting to Board of Directors was also raised for discussion and it was noted that there will be a refreshing of the SOF to

look at the research metrics. Discussion took place and it was agreed to provide a list of KPIs for approval at this committee.

JW/JM/MK

It was also raised the Trust need to advertise research successes more and it was noted that Keith Wilson has focused and improved this over the past 12 months.

7. Report of LCCS

It was noted that there have been several meetings to define the membership and terms of reference are being re-established. These meetings take place every three months and steady progress is being made.

There were no further comments or questions.

8. Ongoing and Planned Research Project reports

It was noted that at present there are 54 open studies, and 31 in the pipeline. The pipeline is looked at very carefully in terms of what is achievable and what will bring in money.

9. Research Finance Report

An overview was provided of the research finances and it was noted that CRN income received is higher than budget due to additional funding for one month of research scholars and 0.5 Pharmacy WTE.

Income from deferred accounts is over budget due to income for additional staff and ad-hoc non-pay expenses funded by deferred accounts.

Trial income invoicing dropped greatly towards the end of the year. Work is continuing to ensure that the information held of EDGE is correct.

Pay is overspent due to over-lapping of posts following maternity leave and new posts funded by external income.

Non-pay is underspent primarily relating to technical adjustments from 2022-23 year end and in year underspends on miscellaneous expenditure.

Comments and questions were welcomed and CFO noted that importance of ensuring that the transactional process has the correct structure.

10. Partnership working and update from the partners

It was noted that LJMU are moving forward with investment more into innovation and connecting this to enterprise and research.

11. Research news and key successes

Colleagues were informed that Dr Jay Wright has been included as an

author on a New England Journal of Medicine paper for implanting 3 leadless pacemakers that talk to a subcutaneous ICD. Only 150 have been implanted worldwide.

12. Report on Innovation agenda

An update was provided on the innovation agenda and colleagues were informed that this work will be picked up by Thomas Pharaoh, Director of Strategy. It was agreed that a position paper would be brought to the next meeting.

TP

13. Minutes from the last operational R&I committee

R&I colleagues were asked to note the minutes from the last operational R&I committee.

There were no further comments or questions.

14. AoB

Colleagues were informed that there is now a new person in charge of the BHF.

Chair informed colleagues that Jenny Crooks, Deputy Director of Research and Innovation is leaving the Trust.

Date and time of next meeting:

Tuesday 16th July, 2.00pm – 3.30pm, MS Teams